LOTUS™ Valve Superior to CoreValve®*

In Primary Efficacy Endpoint **

LOTUS Valve = 16.7%  v. CoreValve Platform = 29.0%
Superiority P < 0.001

Presented by T. Feldman MD at EuroPCR 2017

View the data highlights here.
Or read the full deck as presented at EuroPCR

Superior PVL performance with significantly lower PVL.


Presented by T. Feldman MD at EuroPCR 2017

 

Superior procedural outcomes with a signifcantly lower disabling stroke rate.


Presented by T. Feldman MD at EuroPCR 2017

 

Superior procedural outcomes with 0% malpositioning and 0% TAV in TAV procedures. The LOTUS Valve is designed to allow full valve assessment before release and to be repositionable after 100% valve deployment. 


Presented by T. Feldman MD at EuroPCR 2017